Lee, Jung-Min

National Cancer Institute · Center for Cancer Research

1 paper on CoChatORCID 0000-0001-5456-7449

Most cited papers

Verified
Combination of PARP inhibitor olaparib, and PD-L1 inhibitor durvalumab, in recurrent ovarian cancer: a proof-of-concept phase II study
Lampert, E. J., Zimmer, A., Padget, M., Cimino-Mathews, A., Nair, J. R., Liu, Y., Swisher, E. M., Hodge, J. W., Nixon, A. B., Nichols, E., et al. (2020) · Clinical Cancer Research
PARP inhibition in cancer therapyOvarian cancer diagnosis and treatment
Cited by 220

Go further with a free account

Verify every reference, keep papers in a library, and ask questions across them.

Sign up - it is free